Precision
medicine
envisages
the
integration
of
an
individual’s
clinical
and
biological
features
obtained
from
laboratory
tests,
imaging,
high-throughput
omics
health
records,
to
drive
a
personalised
approach
diagnosis
treatment
with
higher
chance
success.
As
only
up
half
patients
respond
medication
prescribed
following
current
one-size-fits-all
strategy,
need
for
more
is
evident.
One
routes
transforming
healthcare
through
precision
pharmacogenomics
(PGx).
Around
95%
population
estimated
carry
one
or
actionable
pharmacogenetic
variants
over
75%
adults
50
years
old
are
on
prescription
known
PGx
association.
Whilst
there
compelling
examples
pharmacogenomic
implementation
in
practice,
case
cardiovascular
still
evolving.
In
this
review,
we
shall
summarise
status
diseases
look
at
key
enablers
barriers
practice.
Health Science Reports,
Год журнала:
2024,
Номер
7(11)
Опубликована: Окт. 30, 2024
ABSTRACT
Background
and
Aims
Cardiovascular
diseases
are
responsible
for
a
high
mortality
rate
globally.
Precision
medicine
has
emerged
as
an
essential
tool
improving
cardiovascular
disease
outcomes.
In
this
context,
using
advanced
imaging
exams
is
fundamental
in
precision
medicine,
enabling
more
accurate
diagnoses
customized
treatments.
This
review
aims
to
provide
concise
on
how
supports
highlighting
its
benefits,
challenges,
future
directions.
Methods
A
literature
was
carried
out
the
Pubmed
Google
Scholar
databases,
search
strategies
that
combined
terms
such
diseases,
tests.
Results
More
analysis
aimed
at
diagnosing
describing
greater
detail
made
possible
by
tests
cardiac
computed
tomography,
magnetic
resonance
imaging,
positron
emission
tomography.
addition,
aggregation
of
data
with
other
omics
allows
personalized
treatment
better
description
patient
profiles.
Conclusion
The
use
medicine.
Although
there
still
technical
ethical
obstacles,
it
collaboration
between
health
professionals,
well
investments
technology
education
disseminate
consequently
promote
improved
The Senior Care Pharmacist,
Год журнала:
2024,
Номер
39(4), С. 129 - 131
Опубликована: Март 26, 2024
Enormous
strides
have
been
made
in
sequencing
technology,
multi-gene
panels,
evidence-based
guidelines,
and
actionable
results.
We
moving
from
reactive
pharmacogenomic
testing
based
on
single
gene
analysis
to
broad
pre-emptive
testing,
where
the
pharmacogenetic
information
is
available
electronic
health
records
prescription
systems
enabling
dosing
decisions
before
a
written.
Horizon Nexus Journal.,
Год журнала:
2024,
Номер
2(4), С. 29 - 41
Опубликована: Окт. 31, 2024
The
article
discusses
the
application
of
personalized
medicine
and
pharmacogenomics
in
treatment
cardiovascular
disease,
highlighting
their
ability
to
improve
drug
efficacy
reduce
adverse
effects.
Through
a
literature
review,
study
examines
how
genetic
variants
genes
such
as
CYP2C19
SLCO1B1
influence
response
common
drugs
statins
clopidogrel.
results
indicate
that
tailoring
doses
according
patient's
profile
not
only
improves
clinical
outcomes,
but
also
reduces
incidence
serious
side
effects,
myopathies
thrombosis.
Despite
these
benefits,
implementation
faces
significant
barriers,
high
costs
testing
lack
access
advanced
technology
some
regions.
concludes
that,
although
has
potential
transform
diseases,
its
widespread
adoption
will
depend
on
overcoming
barriers.
Precision
medicine
envisages
the
integration
of
an
individual’s
clinical
and
biological
features
obtained
from
laboratory
tests,
imaging,
high-throughput
omics
health
records,
to
drive
a
personalised
approach
diagnosis
treatment
with
higher
chance
success.
As
only
up
half
patients
respond
medication
prescribed
following
current
one-size-fits-all
strategy,
need
for
more
is
evident.
One
routes
transforming
healthcare
through
precision
pharmacogenomics
(PGx).
Around
95%
population
estimated
carry
one
or
actionable
pharmacogenetic
variants
over
75%
adults
50
years
old
are
on
prescription
known
PGx
association.
Whilst
there
compelling
examples
pharmacogenomic
implementation
in
practice,
case
cardiovascular
still
evolving.
In
this
review,
we
shall
summarise
status
diseases
look
at
key
enablers
barriers
practice.
Precision
medicine
envisages
the
integration
of
an
individual's
clinical
and
biological
features
obtained
from
laboratory
tests,
imaging,
high-throughput
omics
health
records,
to
drive
a
personalised
approach
diagnosis
treatment
with
higher
chance
success.
As
only
up
half
patients
respond
medication
prescribed
following
current
one-size-fits-all
strategy,
need
for
more
is
evident.
One
routes
transforming
healthcare
through
precision
pharmacogenomics
(PGx).
Around
95%
population
estimated
carry
one
or
actionable
pharmacogenetic
variants
over
75%
adults
50
years
old
are
on
prescription
known
PGx
association.
Whilst
there
compelling
examples
pharmacogenomic
implementation
in
practice,
case
cardiovascular
still
evolving.
In
this
review,
we
shall
summarise
status
diseases
look
at
key
enablers
barriers
practice.
Precision
medicine
envisages
the
integration
of
an
individual’s
clinical
and
biological
features
obtained
from
laboratory
tests,
imaging,
high-throughput
omics
health
records,
to
drive
a
personalised
approach
diagnosis
treatment
with
higher
chance
success.
As
only
up
half
patients
respond
medication
prescribed
following
current
one-size-fits-all
strategy,
need
for
more
is
evident.
One
routes
transforming
healthcare
through
precision
pharmacogenomics
(PGx).
Around
95%
population
estimated
carry
one
or
actionable
pharmacogenetic
variants
over
75%
adults
50
years
old
are
on
prescription
known
PGx
association.
Whilst
there
compelling
examples
pharmacogenomic
implementation
in
practice,
case
cardiovascular
still
evolving.
In
this
review,
we
shall
summarise
status
diseases
look
at
key
enablers
barriers
practice.
Precision
medicine
envisages
the
integration
of
an
individual's
clinical
and
biological
features
obtained
from
laboratory
tests,
imaging,
high-throughput
omics
health
records,
to
drive
a
personalised
approach
diagnosis
treatment
with
higher
chance
success.
As
only
up
half
patients
respond
medication
prescribed
following
current
one-size-fits-all
strategy,
need
for
more
is
evident.
One
routes
transforming
healthcare
through
precision
pharmacogenomics
(PGx).
Around
95%
population
estimated
carry
one
or
actionable
pharmacogenetic
variants
over
75%
adults
50
years
old
are
on
prescription
known
PGx
association.
Whilst
there
compelling
examples
pharmacogenomic
implementation
in
practice,
case
cardiovascular
still
evolving.
In
this
review,
we
shall
summarise
status
diseases
look
at
key
enablers
barriers
practice.
Precision
medicine
envisages
the
integration
of
an
individual’s
clinical
and
biological
features
obtained
from
laboratory
tests,
imaging,
high-throughput
omics
health
records,
to
drive
a
personalised
approach
diagnosis
treatment
with
higher
chance
success.
As
only
up
half
patients
respond
medication
prescribed
following
current
one-size-fits-all
strategy,
need
for
more
is
evident.
One
routes
transforming
healthcare
through
precision
pharmacogenomics
(PGx).
Around
95%
population
estimated
carry
one
or
actionable
pharmacogenetic
variants
over
75%
adults
50
years
old
are
on
prescription
known
PGx
association.
Whilst
there
compelling
examples
pharmacogenomic
implementation
in
practice,
case
cardiovascular
still
evolving.
In
this
review,
we
shall
summarise
status
diseases
look
at
key
enablers
barriers
practice.
Precision
medicine
envisages
the
integration
of
an
individual's
clinical
and
biological
features
obtained
from
laboratory
tests,
imaging,
high-throughput
omics
health
records,
to
drive
a
personalised
approach
diagnosis
treatment
with
higher
chance
success.
As
only
up
half
patients
respond
medication
prescribed
following
current
one-size-fits-all
strategy,
need
for
more
is
evident.
One
routes
transforming
healthcare
through
precision
pharmacogenomics
(PGx).
Around
95%
population
estimated
carry
one
or
actionable
pharmacogenetic
variants
over
75%
adults
50
years
old
are
on
prescription
known
PGx
association.
Whilst
there
compelling
examples
pharmacogenomic
implementation
in
practice,
case
cardiovascular
still
evolving.
In
this
review,
we
shall
summarise
status
diseases
look
at
key
enablers
barriers
practice.
Precision
medicine
envisages
the
integration
of
an
individual’s
clinical
and
biological
features
obtained
from
laboratory
tests,
imaging,
high-throughput
omics
health
records,
to
drive
a
personalised
approach
diagnosis
treatment
with
higher
chance
success.
As
only
up
half
patients
respond
medication
prescribed
following
current
one-size-fits-all
strategy,
need
for
more
is
evident.
One
routes
transforming
healthcare
through
precision
pharmacogenomics
(PGx).
Around
95%
population
estimated
carry
one
or
actionable
pharmacogenetic
variants
over
75%
adults
50
years
old
are
on
prescription
known
PGx
association.
Whilst
there
compelling
examples
pharmacogenomic
implementation
in
practice,
case
cardiovascular
still
evolving.
In
this
review,
we
shall
summarise
status
diseases
look
at
key
enablers
barriers
practice.
